朱秀媛, 宋振玉. N-C14甲酰溶肉瘤素在肿瘤病人的吸收和排泄J. 药学学报, 1965, 12(12): 793-797.
引用本文: 朱秀媛, 宋振玉. N-C14甲酰溶肉瘤素在肿瘤病人的吸收和排泄J. 药学学报, 1965, 12(12): 793-797.
CHU HSIU-YUAN SUNG CHEN-YU, . THE ABSORPTION AND EXCRETION OF N-FORMYLSARCOLYSINE-C14 IN PATIENTS WITH MALIGNANT DISEASEJ. Acta Pharmaceutica Sinica, 1965, 12(12): 793-797.
Citation: CHU HSIU-YUAN SUNG CHEN-YU, . THE ABSORPTION AND EXCRETION OF N-FORMYLSARCOLYSINE-C14 IN PATIENTS WITH MALIGNANT DISEASEJ. Acta Pharmaceutica Sinica, 1965, 12(12): 793-797.

N-C14甲酰溶肉瘤素在肿瘤病人的吸收和排泄

THE ABSORPTION AND EXCRETION OF N-FORMYLSARCOLYSINE-C14 IN PATIENTS WITH MALIGNANT DISEASE

  • 摘要: 精原细胞瘤病人口服NC14-甲酰溶肉瘤素15毫克(约30微居里)后72小时内,C14自尿及大便的总排出量为剂量的68.0-77.4%;其中由尿及大便所排出的放射性各约半量.尿中的放射性绝大部分为给药后前5小时内排出的,大便中的放射性则主要在给药后48小时(两次大便,便秘患者除外)内排出.在服药后24小时内,血液(全血、血浆及血球)、唾液及呼出的二氧化碳仅有痕迹量放射性存在.口服N-甲C14的同时,口服大量非标记的N-甲,并未显著地影响C14的排泄.

     

    Abstract: N-Formylsarcolysine (NF) labelled with C14 in the formyl position (NF-C14) was used in this investigation to study the absorption and excretion of radioactivity in four patients suffering from seminoma. Seventy-two hours after an oral dose of 15mg of NF-C14 (about 30 μC, one patient was administered 100mg of unlabelled NF in addition to the labelled compound), 36.6, 33.2, and 34.1% of the administered radioactivity were excreted in the urine in three patients. However, most (89-97%) of the urinary radioactivity was excreted in the first 5-hour urine. During the 72-hour period, 33.5, 36.2, and 43.3% of the dose were recovered in the faeces of these patients, and of these, 86-99% was accounted for in the first 48-hour specimen. The fourth patient who had constipation excreted 28.8% of the administered radioactivity in the urine in 72 hours, most (92%) of which was re- covered in the first 5-hour urine sample. About 39.2% was recovered from the faeces in 6 days, mainly (98%) in the first 4 days (including the first and the second faeces specimen voided since the drug administration). Only trace of radioactivity was detected in the blood, saliva, and expired carbon dioxide in the first 24-hour period after NF-C14 administration. These results indicate that, in patients given NF-C14 orally, the radioactivity was ab- sorbed rapidly but incompletely. However, the possibility that the absorbed radioactivity reentered the intestinal tract and was excreted in the faeces should not be excluded. It appears that the absorption and excretion of radioactivity after per oral NF-C14 was not affected by the simultaneous administration of a large dose of the unlabelled drug.

     

/

返回文章
返回